1. Introduction {#sec1-marinedrugs-14-00036}
===============

Voltage-gated sodium channels (VGSCs) are responsible for the rising phase of the action potential in excitable cells such as neurons, cardiac myocytes and skeletal muscle myocytes \[[@B1-marinedrugs-14-00036],[@B2-marinedrugs-14-00036]\]. VGSCs are composed of voltage-sensing and pore-forming elements in one principal α-subunit and one or two auxiliary β-subunits which alter the channel physiological properties and subcellular localization \[[@B3-marinedrugs-14-00036]\]. Based on the amino acid similarity of the α-subunit isoforms, nine VGSC subtypes have been described termed Na~v~1.1--Na~v~1.9 \[[@B4-marinedrugs-14-00036]\].

VGSCs represent the molecular targets for a broad range of potent neurotoxins that bind to at least six distinct neurotoxin sites on the sodium channel α-subunit and affect the ion permeation and gating of sodium channels \[[@B3-marinedrugs-14-00036]\]. These toxins include tetrodotoxin (TTX), saxitoxin, and μ-conotoxin (site 1); lipid-soluble alkaloid toxins, including batrachotoxin, veratridine, aconitine, and grayanotoxin (site 2); polypeptide sea anemone and α-scorpion toxins (site 3); β-scorpion toxins (site 4); marine toxins such as brevetoxins (PbTxs) and ciguatoxins (site 5); and δ-conotoxins (site 6) \[[@B5-marinedrugs-14-00036]\]. In addition, pyrethroid insecticides act at a distinctive site on the sodium channel α-subunit to enhance channel activity by shifting activation to more negative membrane potentials as well as by delaying inactivation \[[@B6-marinedrugs-14-00036]\].

The expression of sodium channel α-subunits is tissue-dependent. Na~v~1.7 is preferentially expressed in the nociceptive neurons such as dorsal root ganglion and trigeminal ganglion as well as the sympathetic ganglion neurons \[[@B7-marinedrugs-14-00036]\] producing "threshold currents" close to resting potential, amplifying small depolarization such as generator potentials \[[@B8-marinedrugs-14-00036]\]. The role of Na~v~1.7 in the nociception and pain has been well established \[[@B9-marinedrugs-14-00036]\]. Several gain-of-function mutations in *SCN9A* which encodes Na~v~1.7 caused primary erythromelalgia, resulting in burning pain and flushing \[[@B10-marinedrugs-14-00036],[@B11-marinedrugs-14-00036]\]. On the contrary, the inflammatory pain responses were reduced or abolished in nociceptor-specific Na~v~1.7 knock-out mice \[[@B12-marinedrugs-14-00036],[@B13-marinedrugs-14-00036]\]. Deleting *SCN9A* in both sensory and sympathetic neurons abolished the pain sensations and recapitulated the pain-free phenotype seen in humans with *SCN9A* loss-of-function mutations \[[@B13-marinedrugs-14-00036]\]. These observations highlighted Na~v~1.7 as a potentially useful target for the development of novel analgesics.

Patch clamp electrophysiology is the gold standard for characterizing compound activity on the ion channels. While irreplaceable to study the millisecond kinetics of activation and inactivation of VGSCs, the patch clamp technique is laborious and extremely slow, which has greatly limited the utility of this technique to discover novel chemotypes targeting on ion channels. Recently, the automated, multichannel, voltage-clamp instruments provided the possibility for screening larger libraries of compounds. Unfortunately, automated electrophysiology is still quite expensive and is available in few academic laboratories \[[@B14-marinedrugs-14-00036],[@B15-marinedrugs-14-00036]\].

Thus, higher-throughput, less expensive techniques are valuable alternatives to automated electrophysiology. Recently, researchers have developed several fluorescence-based rapid throughput assays for ion channel ligands discovery. The high throughput screening (HTS) thallium (Tl^+^)-flux assay has been developed to discover modifiers of K^+^ channels \[[@B16-marinedrugs-14-00036],[@B17-marinedrugs-14-00036],[@B18-marinedrugs-14-00036]\], K^+^-coupled chloride cotransporters \[[@B19-marinedrugs-14-00036]\], and Na^+^ and K^+^-coupled chloride cotransporters \[[@B20-marinedrugs-14-00036]\]. Many efforts have been made to develop the functional HTS assays to identify the VGSC modifiers. These assays including using sodium specific fluorescence dye, sodium-binding benzofuran isophthalate/acetoxymethyl ester (SBFI/AM) in neurons \[[@B5-marinedrugs-14-00036],[@B21-marinedrugs-14-00036],[@B22-marinedrugs-14-00036]\] and in heterologously expressed VGSCs cells \[[@B23-marinedrugs-14-00036]\]. However, the sodium bounded SBFI/AM fluorescence required excitations at two wavelengths (340 and 380 nm) which limited the throughput. In addition, in a heterologously expressed system, the fluorescence signal to noise ratio of the sodium channel agonists at defined recognition sites was minimal \[[@B23-marinedrugs-14-00036]\]. Membrane potential dye such as DiSBAC2(3) was also used to develop the HTS assay for discovering the VGSC antagonists \[[@B24-marinedrugs-14-00036],[@B25-marinedrugs-14-00036]\]. In addition to its two wavelength recording (460 nm and 580 nm), the robust FRET fluorescence signals only can be achieved by co-application of two sodium channel agonists simultaneously. This co-application of two agonists resulted in a low Z′ value (0.15--0.45) which was not suitable for HTS assay \[[@B25-marinedrugs-14-00036]\]. Therefore, an agonist which can efficaciously activate the VGSCs is needed. Antillatoxin (ATX), a structurally unique lipopeptide produced by the marine cyanobacterium, *Lyngbya majuscula*, is a VGSC agonist \[[@B5-marinedrugs-14-00036],[@B23-marinedrugs-14-00036],[@B26-marinedrugs-14-00036],[@B27-marinedrugs-14-00036]\]. ATX binds to a topological distinct neurotoxin site and allosterically potentiates the VGSC agonists-induced \[^3^H\]batrachotoxin binding \[[@B27-marinedrugs-14-00036]\]. More importantly, functional analysis has demonstrated that ATX displays the highest efficacy on the stimulation of sodium influx compared to other VGSC agonists \[[@B5-marinedrugs-14-00036],[@B23-marinedrugs-14-00036]\].

In this study, we compared the influence of a range of VGSC agonists which bound to VGSC distinct neurotoxin sites using FLIPR membrane potential (FMP) blue dye in a 96-well format in hNa~v~1.7-HEK-293 cells. Among the agonists tested, only ATX produced a potent and efficacious membrane depolarization, providing a good signal/noise ratio. We further demonstrated that six VGSC antagonists including lidocaine, lamotrigine, phenytoin, carbamazepine, riluzole, and 2-amino-6-trifluoromethylthiobenzothiazole (SKA-19) all concentration-dependently inhibited ATX response with IC~50~ values comparable to that reported from patch-clamp experiments. These data suggested that ATX might represent a useful probe for developing an HTS assay to identify Na~v~1.7 antagonists.

2. Results {#sec2-marinedrugs-14-00036}
==========

2.1. Influence of VGSC Agonists on Membrane Depolarization in HEK-293 Cells Stably Expressing hNa~v~1.7 {#sec2dot1-marinedrugs-14-00036}
-------------------------------------------------------------------------------------------------------

Previous studies have demonstrated that VGSC agonists such as veratridine, brevetoxin-2 (PbTx-2) had minimal effects on the stimulation of sodium influx or membrane depolarization in HEK-293 cells stably expressing VGSCs \[[@B23-marinedrugs-14-00036],[@B25-marinedrugs-14-00036]\]. To identify an efficacious VGSC agonist which can provide a good signal/noise ratio, we examined the response on membrane depolarization in hNa~v~1.7 expressed HEK-293 cells of five VGSC agonists which bound to topologically distinct neurotoxin sites including veratridine (VER, neurotoxin site 2), BmK NT1 (a site 3 α-scorpion toxin) \[[@B22-marinedrugs-14-00036]\], PbTx-2 (neurotoxin site 5) \[[@B5-marinedrugs-14-00036]\], deltamethrin (unrecognized neurotoxin site) \[[@B21-marinedrugs-14-00036]\], and ATX (unrecognized neurotoxin site) \[[@B23-marinedrugs-14-00036]\]. ATX produced a robust membrane depolarization in a concentration-dependent manner ([Figure 1](#marinedrugs-14-00036-f001){ref-type="fig"}A). Veratridine (up to 20 μM), BmK NT1 (up to 10 μM) and deltamethrin (up to 10 μM) produced a marginal response on the membrane depolarization ([Figure 1](#marinedrugs-14-00036-f001){ref-type="fig"}B,C,E). The neurotoxin site 5 agonist PbTx-2 was without effect on the membrane potential change in hNa~v~1.7-HEK-293 cells ([Figure 1](#marinedrugs-14-00036-f001){ref-type="fig"}D). The EC~50~ value for ATX-stimulated membrane depolarization (area under curve, AUC *vs* Log (concentration)) was 7.8 ± 2.9 nM with a maximal response of 11.7-fold of vehicle control ([Figure 2](#marinedrugs-14-00036-f002){ref-type="fig"}). Compared to the maximal ATX response (efficacy defined as 1), the maximal responses of veratridine, deltamethrin and BmK NT1 were only 0.11, 0.10 and 0.05, respectively ([Figure 2](#marinedrugs-14-00036-f002){ref-type="fig"}).

![Time-response relationships for ATX (**A**); veratridine (VER) (**B**); BmK NT1 (**C**); PbTx-2 (**D**); and deltamethrin (DM) (**E**) on membrane depolarization in hNa~v~1.7-HEK-293 cells. This experiment was performed in three independent cultures, each in triplicate.](marinedrugs-14-00036-g001){#marinedrugs-14-00036-f001}

![Concentration-response relationship curves for ATX, veratridine, deltamethrin, BmK NT1 and PbTx-2 induced membrane potential changes. Each data point represents the mean ± SEM from two experiments, each in triplicates. ATX produced an efficacious response in the membrane depolarization while veratridine, deltamethrin and BmK NT1 only produced marginal response with efficacies of 0.11, 0.10, and 0.05 respectively. PbTx-2 was without effect on the membrane depolarization.](marinedrugs-14-00036-g002){#marinedrugs-14-00036-f002}

2.2. ATX-Induced Membrane Depolarization Was Dependent on the Activation of hNa~v~1.7 {#sec2dot2-marinedrugs-14-00036}
-------------------------------------------------------------------------------------

Given the efficacious response on the membrane potential change in hNa~v~1.7-HEK-293 cells, we examined whether this membrane depolarization was from the activation of hNa~v~1.7. Pre-treatment of TTX, a pore blocker of VGSC, concentration-dependently suppressed the ATX (10 nM)-induced membrane depolarization with an IC~50~ value of 49.8 nM (31.0--80.4 nM, 95% CI) ([Figure 3](#marinedrugs-14-00036-f003){ref-type="fig"}A,B). In null HEK-293 cells, ATX produced minimal response on the membrane depolarization which, compared to the ATX-induced response in hNa~v~1.7-HEK-293 cells, was marginal ([Figure 3](#marinedrugs-14-00036-f003){ref-type="fig"}C--E).

![ATX-produced membrane depolarization was dependent on the activation of hNa~v~1.7. (**A**) TTX antagonized ATX-induced membrane depolarization in hNa~v~1.7 HEK-293 cells as a function of time; (**B**) Concentration-response curve for TTX suppressed ATX-induced depolarization in hNa~v~1.7 HEK 293 cells. Each data point represents the mean ± SEM from two independent cultures performed in triplicate; (**C**) and (**D**) ATX response on membrane depolarization in hNa~v~1.7-HEK-293 cells and null HEK-293 cells as a function of time, respectively; (**E**) Concentration-response relationships of ATX response on membrane depolarization in hNa~v~1.7-HEK-293 cells and null HEK-293 cells. This experiment was performed in two independent cultures, each in triplicate with similar results.](marinedrugs-14-00036-g003){#marinedrugs-14-00036-f003}

2.3. Z′ Factor Determination {#sec2dot3-marinedrugs-14-00036}
----------------------------

Given the efficacious ATX response on the membrane depolarization which was solely dependent on the hNa~v~1.7 activation, we determined Z′ factor to test the suitability to use ATX and membrane potential dye for HTS assay. As shown in [Figure 4](#marinedrugs-14-00036-f004){ref-type="fig"}, 30 nM ATX produced a robust, yet consistent response on the membrane depolarization. The calculated Z′ value was 0.7598.

![A representative 96-well plate for ATX (30 nM) response on the membrane depolarization. The cells in Columns 2 to 11 were exposed to 30 nM of ATX. The Columns 1 and 12 were negative controls (0.1% DMSO). ATX produced a robust, yet consistent membrane depolarization. The Z′ factor was calculated to be 0.7589. This experiment was performed in two independent cultures.](marinedrugs-14-00036-g004){#marinedrugs-14-00036-f004}

2.4. Influence of an Array of VGSC Antagonists on ATX-Induced Membrane Depolarization {#sec2dot4-marinedrugs-14-00036}
-------------------------------------------------------------------------------------

We next tested the influence of six VGSC antagonists on ATX (10 nM)-induced membrane depolarization. All the VGSC antagonists tested including lidocaine, lamotrigine, phenytoin, carbamazepine, riluzole, and SKA-19 produced concentration-dependent inhibition of ATX (10 nM)-induced membrane depolarization ([Figure 5](#marinedrugs-14-00036-f005){ref-type="fig"}). The IC~50~ values for SKA-19, riluzole, phenytoin, lamotrigine, carbamazepine, and lidocaine were 2.02 (1.49--2.74 μM, 95% CI), 3.58 (2.67--4.80 μM, 95% CI), 18.7 (11.8--29.7 μM, 95% CI), 66.3 (40.7--108.1 μM, 95% CI), 77.7 (49.9--121.0 μM, 95% CI) and 150.6 (92.9--244.0 μM, 95% CI), respectively ([Table 1](#marinedrugs-14-00036-t001){ref-type="table"}). The IC~50~ values generated here are consistent to that generated from patch clamp ([Table 1](#marinedrugs-14-00036-t001){ref-type="table"}). It should be noted that riluzole, SKA-19, carbamazepine, and lamotrigine all produced nearly complete inhibition on ATX-induced membrane depolarization. However, the maximal inhibition of lidocaine and phenytoin on ATX-induced depolarization was somewhat smaller representing a maximal suppressing of 80.2% ± 5.8% and 78.8% ± 5.5%, respectively.

![Influence of VGSC antagonists including riluzole, SKA-19, phenytoin, lidocaine, carbamazepine, and lamotrigine on ATX (10 nM)-induced membrane depolarization. Data are presented as percentage of 10 nM ATX-induced fluorescence change. Each data point represents the mean ± SEM from two experiments, each in triplicates.](marinedrugs-14-00036-g005){#marinedrugs-14-00036-f005}
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###### 

Comparison of the IC~50~ values generated from this study with that from patch clamp.

  Compounds       IC~50~ (μM) (95% CI)   Patch-Clamp IC~50~ (μM)   Reference
  --------------- ---------------------- ------------------------- ---------------------------------
  SKA-19          2.02 (1.49--4.74)      5.8                       \[[@B28-marinedrugs-14-00036]\]
  Riluzole        3.58 (2.67--4.80)      2                         \[[@B29-marinedrugs-14-00036]\]
  Phenytoin       18.7 (11.8--29.7)      31.6                      \[[@B24-marinedrugs-14-00036]\]
  Lamotrigine     66.3 (40.6--108.1)     79                        \[[@B30-marinedrugs-14-00036]\]
  Carbamazepine   77.7 (49.9--121.0)     101                       \[[@B30-marinedrugs-14-00036]\]
  Lidocaine       150.6 (92.9--244.0)    110                       \[[@B31-marinedrugs-14-00036]\]

3. Discussion {#sec3-marinedrugs-14-00036}
=============

In primary cultured neuronal preparation, the VGSC agonists ATX, veratridine, BmK NT1, PbTx-2 and deltamethrin which bound to topologically distinct neurotoxin sites all produced robust and significant sodium influx with distinct efficacies \[[@B5-marinedrugs-14-00036],[@B22-marinedrugs-14-00036],[@B23-marinedrugs-14-00036]\]. However, several studies have pointed out that in heterologous expression systems, these VGSC agonists produced a minimal response on both sodium influx and membrane potential \[[@B5-marinedrugs-14-00036],[@B25-marinedrugs-14-00036]\]. In this study, we examined the ability of five VGSC agonists which bound to topologically distinctive neurotoxin sites to stimulate the membrane depolarization in hNa~v~1.7-HEK-293 cells. Consistent with the previous studies \[[@B23-marinedrugs-14-00036],[@B25-marinedrugs-14-00036]\], veratridine (neurotoxin site 2) only produced minimal response on the membrane depolarization whereas PbTx-2 (neurotoxin site 5) was without effect in hNa~v~1.7-HEK-293 cells. We further demonstrated that deltamethin, which bound to an undefined neurotoxin site delaying the inactivation of the VGSCs \[[@B32-marinedrugs-14-00036]\], produced minimal response on the membrane potential changes. In addition, a scorpion toxin, BmK NT1 which likely bound to neurotoxin site 3 and prolonged the inactivation of the VGSCs in neurons \[[@B22-marinedrugs-14-00036]\] only produced marginal response to stimulate membrane depolarization. However, ATX produced an efficacious response on the membrane depolarization. Although the sodium channel expression density may partially account for the response discrepancy between neuronal and heterologously expression system \[[@B33-marinedrugs-14-00036]\], the hNa~v~1.7-HEK-293 cells had little β-subunits co-expression. Sodium channel β-subunits regulate α-subunit function at multiple levels including mRNA expression, channel stabilization/trafficking and direct channel modulation \[[@B34-marinedrugs-14-00036]\]. In addition, the resting membrane potential for HEK-293 cells is relatively depolarized (−35 ± 5 mV) \[[@B35-marinedrugs-14-00036]\]. At this depolarized resting membrane potential, most hNa~v~1.7 channels are in inactivated state \[[@B35-marinedrugs-14-00036]\]. Veratridine, BmK NT1, PbTx-2 and deltamethrin were demonstrated to primarily delay the VGSCs inactivation kinetics, but not the activation kinetics \[[@B22-marinedrugs-14-00036],[@B32-marinedrugs-14-00036],[@B36-marinedrugs-14-00036]\], an alternative explanation for these four VGSC agonists only producing marginal response in hNa~v~1.7-HEK-293 cells. Although the detailed electrophysiological characterization of ATX on the VGSC remained to be established, the efficacious response on the membrane depolarization in hNa~v~1.7-HEK-293 cells highly suggested that ATX response was not dependent on the β-subunits. The unique efficacious response of ATX also suggested that ATX may interact preferentially with the inactivated state of VGSC α-subunits.

The ATX response in hNa~v~1.7-HEK-293 cells was from activation of hNa~v~1.7 inasmuch as TTX completely suppressed the ATX-induced membrane depolarization. Furthermore, in null HEK-293 cells, ATX produced marginal membrane depolarization. The marginal membrane depolarization possibly was derived from the endogenously expressed VGSCs in null HEK-293 cells \[[@B37-marinedrugs-14-00036]\]. A rapid throughput assay to identify Na~v~1.7 antagonists has been developed by co-application of veratridine and a scorpion toxin SVqq to achieve the robust fluorescence signals through activating VGSCs. However, this co-application of two agonists resulted in a low Z′ value (0.15--0.45) \[[@B25-marinedrugs-14-00036]\], which was not suitable for the HTS assay. We demonstrated here that ATX produced a robust as well as consistent fluorescence change in a whole 96-well plate with a Z′ value of 0.7589. The Z′ value greater than 0.5 was thought to be suitable for the HTS assay \[[@B25-marinedrugs-14-00036]\].

In this study, we further demonstrated that an array of VGSC antagonists, including SKA-19, riluzole, phenytoin, lamotrigine, carbamazepine, and lidocaine all concentration-dependently suppressed ATX-induced membrane depolarization. It has been demonstrated that the IC~50~ values generated from a fluorescence-based assay is typically five-fold less potent than that generated from patch-clamp \[[@B24-marinedrugs-14-00036],[@B30-marinedrugs-14-00036]\]. However, we demonstrated that the IC~50~ values for these VGSC inhibitors generated in this study were consistent with that from patch-clamp experiments \[[@B24-marinedrugs-14-00036],[@B28-marinedrugs-14-00036],[@B29-marinedrugs-14-00036],[@B30-marinedrugs-14-00036],[@B31-marinedrugs-14-00036],[@B38-marinedrugs-14-00036],[@B39-marinedrugs-14-00036]\] ([Table 1](#marinedrugs-14-00036-t001){ref-type="table"}). Riluzole has been reported to suppress TTX-sensitive VGSC current in inactivated state with IC~50~ values of 2 μM in dorsal root ganglion neurons, in which Na~v~1.7 was the major TTX-sensitive VGSC subtype. At resting state, riluzole displayed a much lower affinity with an IC~50~ value of 90 μM, suggesting riluzole preferred to bind to the inactivated state of VGSCs \[[@B29-marinedrugs-14-00036]\]. We demonstrated that riluzole inhibited the ATX-induced membrane potential changes with an IC~50~ value of 3.58 μM which was comparable to its affinity in the inactivated state \[[@B29-marinedrugs-14-00036]\]. SKA-19, a thioanalog of riluzole, is a use- and state-dependent VGSC antagonist with IC~50~ value of 5.8 ± 2.6 μM. We demonstrated here that SKA-19 suppressed the ATX (10 nM)-induced membrane depolarization in hNa~v~1.7-HEK-293 cells with an IC~50~ value of 2.02 μM, a value similar to that from voltage-patch clamp experiment \[[@B28-marinedrugs-14-00036]\]. The anticonvulsants phenytoin, lamotrigine, and carbamazepine were also preferred to bind to inactivated state of VGSCs \[[@B40-marinedrugs-14-00036],[@B41-marinedrugs-14-00036],[@B42-marinedrugs-14-00036],[@B43-marinedrugs-14-00036],[@B44-marinedrugs-14-00036],[@B45-marinedrugs-14-00036],[@B46-marinedrugs-14-00036],[@B47-marinedrugs-14-00036]\]. The affinities for these anticonvulsants on the inactivated state are much higher than that on the closed and open states \[[@B48-marinedrugs-14-00036]\]. We demonstrated that the IC~50~ values for lamotrigine, carbamazepine and phenytoin suppression of ATX-induced membrane depolarization in hNa~v~1.7-HEK-293 cells were 66.3, 77.7 and 18.7 μM, respectively, which were more consistent with their affinities on the inactivated state. The local anesthetics, lidocaine has been reported to affect the steady-state fast inactivation of Na~v~1.7 channels with an IC~50~ value of 110 ± 20 μM \[[@B31-marinedrugs-14-00036]\] which was also consistent with current finding (150.6 μM, 92.9--244.0 μM, 95% CI). Considered together, it appeared that the IC~50~ values generated from current fluorescence-based HTS assay were more consistent with their respective affinity in the inactivated state.

It has been reported that riluzole, lidocaine, phenytoin bound to distinct sites of the sodium channels \[[@B49-marinedrugs-14-00036],[@B50-marinedrugs-14-00036],[@B51-marinedrugs-14-00036],[@B52-marinedrugs-14-00036]\]. For example, riluzole interacts with amino acids residues TYR 1787, LEU 1843 and GLN 1799 located in the transmembrane segment S6 of domain IV of the α-subunit \[[@B53-marinedrugs-14-00036]\]. Lidocaine binds to the local anesthetics site located in the channel pore \[[@B39-marinedrugs-14-00036],[@B54-marinedrugs-14-00036]\]. Phenytoin binds to the S6 segments of domains III and IV of the Na^+^ channel α-subunit \[[@B40-marinedrugs-14-00036],[@B47-marinedrugs-14-00036],[@B55-marinedrugs-14-00036],[@B56-marinedrugs-14-00036]\]. In addition, TTX binds to another neurotoxin site distinct to those use- and steady-state blockers. The comparable IC~50~ values between current study and reported previously suggesting that the fluorescence-based assay developed here was capable of identifying the hNa~v~1.7 inhibitors bound to distinct neurotoxin sites on the α-subunits of VGSCs.

It has been reported that fluorescence-based assays are often subject to high false positive hits \[[@B57-marinedrugs-14-00036],[@B58-marinedrugs-14-00036]\]. Further study was required to screen a chemical library to determine the liability of the assay. Nevertheless, the HTS assay developed here may represent a useful alternative for the primary screen to identify hNa~v~1.7 antagonists with novel pharmacophores.

4. Materials and Methods {#sec4-marinedrugs-14-00036}
========================

4.1. Materials {#sec4dot1-marinedrugs-14-00036}
--------------

FMP blue dye was obtained from Molecular Devices (Sunnyvale, CA, USA). ATX was synthesized as described previously and was characterized to be above 95% purity \[[@B59-marinedrugs-14-00036]\]. G-418, penicillin, streptomycin, heat inactivated fetal bovine serum, poly-[d]{.smallcaps}-lysine (molecular weight \>300,000), riluzole, veratridine and carbamazepine, deltamethrin, PbTx-2, TTX, and lamotrigine were obtained from Sigma-Aldrich (St. louis, MO, USA). SKA-19 was provided by Prof. Wulff at the University of California, Davis as described previously \[[@B28-marinedrugs-14-00036]\] and was characterized to be greater than 95% purity. Lidocaine was purchased from Abcam (Cambridge, MA, USA). The HEK-293 stably expressed Na~v~1.7 was a generous gift from Dr. Lossin (University of California, Davis) and was the same line used as described previously \[[@B28-marinedrugs-14-00036]\].

4.2. Cell Culture {#sec4dot2-marinedrugs-14-00036}
-----------------

Human Embryonic Kidney 293 (HEK-293) cells were cultured in DMEM with glutamine supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin and 0.1 mg/mL streptomycin. HEK-293 cells stably expressed hNa~v~1.7 were cultured in DMEM supplemented with 10% FBS, 100 units/mL penicillin, 0.1 mg/mL streptomycin, and 500 μg/mL G-418. All cells were grown routinely as monolayers on poly-[d]{.smallcaps}-lysine coated T-75 flask in an atmosphere of 5% CO~2~ and 95% humidity at 37 °C.

4.3. Membrane Potential Change Detection {#sec4dot3-marinedrugs-14-00036}
----------------------------------------

Membrane potential changes in HEK-293 or HEK-293 stably expressed hNa~v~1.7 were determined using the FMP blue dye (Molecular Devices, Sunnyvale, CA, USA). The cells were plated onto poly-[d]{.smallcaps}-lysine (10 μg/mL) coated, 96-well, black-walled, clear-bottom plates at an initial density of 20,000 cells/well and cultured for 6 h. Cells were removed of their medium and 150 μL of 1× dye solution (1 bottle dissolved in 50 mL Locke's buffer, in mM: 8.6 HEPES, 5.6 KCl, 154 NaCl, 5.6 Glucose, 1.0 MgCl~2~, 2.3 CaCl~2~, 0.0001 glycine, pH 7.4) was added to each well. Cells were then incubated at room temperature for 30 min. The plate was then transferred to a FLIPR^®TETRA^ (Molecular Devices, Sunnyvale, CA, USA) chamber. Cells were excited at 510--545 nm and emission at 565--625 nm was recorded at 1 s intervals. After recording the basal fluorescence for 120 s, 50 μL of sodium channel agonists at different concentrations (prepared in 1× dye at 4× final drug concentrations) or vehicle (0.4% DMSO, 4×) were added to different wells by an automated, programmable pipetting system. The fluorescence was recorded for additional 5--6 min at a sampling rate of 1 s. To examine the VGSC antagonist response on ATX-stimulated membrane depolarization, after recording the basal fluorescence for 120 s, different concentrations of VGSC antagonists were added to corresponding wells and the fluorescence was recorded for additional 5 min followed by an addition of 40 nM (4×, final concentration, 10 nM) ATX. The fluorescence signals were presented as F/F~0~, where F was defined as the fluorescence at different time points; F~0~ was the basal fluorescence averaged from initial 5 data points.

4.4. Data Analysis {#sec4dot4-marinedrugs-14-00036}
------------------

Time-response and concentration-response relationships curves were generated using GraphPad Prism 5 software (GraphPad Software, Inc., San Diego, CA, USA). The EC~50~ value for VGSC agonists-induced membrane depolarization was determined by non-linear regression analysis using a logistic equation. The IC~50~ values of VGSC antagonists against ATX-induced membrane depolarization was determined by non-linear regression analysis using a logistic equation. Z′ factor was calculated using the following equation as described previously \[[@B60-marinedrugs-14-00036]\]: Z′ = 1 − \[3 SD of sample + 3 SD of control\]/\[mean of sample − mean of control\]. Each experiment was repeated at least twice in independent cultures performed at least in triplicate.

5. Conclusions {#sec5-marinedrugs-14-00036}
==============

The current study investigated an array of VGSC agonists to stimulate the membrane depolarization in hNa~v~1.7-HEK-293 cells. We demonstrated that ATX but not other VGSC agonists tested produced efficacious response on the membrane depolarization. We further demonstrated that ATX can serve as a probe to develop an HTS assay for identifying hNa~v~1.7 antagonist with distinct binding sites.
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